US Stock MarketDetailed Quotes

GANX Gain Therapeutics

Watchlist
  • 3.770
  • +0.040+1.07%
Close Mar 28 16:00 ET
  • 3.850
  • +0.080+2.12%
Post 18:49 ET
61.15MMarket Cap-2204P/E (TTM)

About Gain Therapeutics Company

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Company Profile

SymbolGANX
Company NameGain Therapeutics
Listing Date03/18/2021
Issue Price11.00
Founded2017
CEOMr. Matthias Alder
MarketNASDAQ
Employees32
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address4800 Montgomery Lane,Suite 220
CityBethesda
ProvinceMaryland
CountryUnited States of America
Zip Code20814
Phone1-301-500-1556

Company Executives

  • Name
  • Position
  • Salary
  • Matthias Alder
  • Director, President and Chief Executive Officer
  • 1.08M
  • Dr. Manolo Bellotto
  • Chief Strategy Officer and General Manager
  • 550.05K
  • Gianluca Fuggetta
  • Vice President, Finance, Principal Financial Officer and Principal Accounting Officer
  • --
  • Dr. Khalid Islam, PhD
  • Chairman of the board
  • 94.85K
  • Eric I. Richman
  • Director
  • 1.27M
  • Dr. Dov A. Goldstein, M.D.
  • Independent Director
  • 81.85K
  • Hans Peter Hasler
  • Independent Director
  • 78.35K
  • Dr. Claude Nicaise,M.D.
  • Independent Director
  • 69.85K
  • Gwen A. Melincoff
  • Independent Director
  • 64.85K
  • Jeffrey Riley
  • Independent Director
  • 80.35K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg